期刊文献+

PD-1/PD-L1信号通路的免疫机制及其与心血管疾病相关性的研究进展 被引量:7

Immune Mechanism of PD-1/PD-L1 Pathway and Cardiovascular Diseases
下载PDF
导出
摘要 中国心血管疾病的患病率及病死率逐年上升,严重威胁公众健康。目前有研究认为多种心血管疾病可能与自身免疫失衡有关,其中T细胞的活化起到了关键作用。细胞程序性死亡受体-1/程序性死亡受体1配体-1(PD-1/PD-L1)信号通路作为负性调节通路,被证实介导T细胞功能抑制和耗竭,维持机体免疫自稳。随着其基础研究的不断深入,也被认为与多种心血管疾病密切相关,现就PD-1/PD-L1信号通路近期研究热点及其与心血管系统疾病相关性进行归纳。 In recent years,the prevalence rate and death rate of cardiovascular disease have been increasing year by year in China,and seriously threatening the public health. Emerging evidence indicate that cardiovascular disease may be related to autoimmune,in which T cell activation plays critical roles. Programmed cell death 1(PD-1) as a negative synergistic stimulus molecule,and its ligand 1(PD-L1)can be potent inhibitory signals,which can mediate the function of T cells to maintain the autoimmune stability. While the basic research of this pathway has been deepened,it is also believed to play an important regulatory role in cardiovascular diseases. In this paper,we will discuss the recent progress of PD-1/PD-L pathway and the relationship with cardiovascular disease.
作者 代晶晶 木胡牙提 DAI Jingjing;MUHUYATI(Heart International Medicine Center,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,Xinjiang,China)
出处 《心血管病学进展》 CAS 2019年第2期204-208,共5页 Advances in Cardiovascular Diseases
基金 国家自然科学基金(81560062)
关键词 细胞程序性死亡受体-1 心血管疾病 自身免疫 T细胞 Programmed cell death 1 Cardiovascular disease Autoimmune T cell
  • 相关文献

参考文献3

二级参考文献24

  • 1刘巍,李为民,高成,李悦,孔一慧.CTLA-4基因启动子区单核苷酸多态性与特发性扩张型心肌病的关联研究[J].中华医学遗传学杂志,2006,23(2):198-201. 被引量:5
  • 2Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2008, 29: 270-276.
  • 3Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy[J]. Circ J, 2009, 73:602- 607.
  • 4Miura K, Matsumnri A, Nasermoaddeli A, et al. Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan[J]. Circ J, 2008, 72: 343-348.
  • 5Maron BJ, Towhin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies., an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomies and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[J]. Circulation, 2006, 113: 1807-1816.
  • 6Fu M. Autoimmunity in idiopathic dilated cardiomyopathy: from patients to molecules and back to patients[J]. Int J Cardiol, 2006, 112: 1.
  • 7Okazaki T, Honjo T. PD-1 and PD-1 ligands from discovery to clinical application[J]. Int Immunol, 2007, 19: 813-824.
  • 8Fife BT, Pauken KE. The role of the PD-1 pathway inautoimmunity and peripheral tolerance[J]. Ann New York Aead Sci, 2011, 1217:45-59.
  • 9Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated eardiomyopathy in PD-l-deficicnt miee[J]. Nat Med, 2003, 9: 1477-1483.
  • 10Richardson P, Mckenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies[-J]. Circulation, 1996, 93 841-842.

共引文献6

同被引文献86

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部